FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 756 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia MOST POPULAR Couple Buys Customized SUV To Give Free Rides To Critically Ill... September 11, 2019 England moves to a single-dose HPV vaccine June 21, 2023 FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular... July 31, 2024 Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among... May 7, 2025 Load more HOT NEWS Dad Gets Tattoo On His Chest To Match Daughter’s Scar So... 4 Ways to Manage Setbacks in Your Cancer Recovery: A Young... EMA Recommends Granting a Marketing Authorisation for Tebentafusp FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma
